patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_546425 | REC_0011501 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.9 | 70 | female | 2 | 12 | 6.6 | 1 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:35:59.742014+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819347 | REC_0011502 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 7.3 | 55 | male | 0 | 0 | 5.7 | 0 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:35:59.742245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_318410 | REC_0011503 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 13 | 66 | female | 1 | 24 | 4.8 | 4 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.742477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_945703 | REC_0011504 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.7 | 68 | female | 1 | 3 | 4.9 | 8 | sotorasib 960 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:59.742709+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447754 | REC_0011505 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 10.7 | 68 | female | 0 | 26 | 6.1 | 2 | osimertinib 80 mg daily | 23.2 | false | MSI-H | 2026-03-15T05:35:59.742939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292975 | REC_0011506 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.1 | 61 | male | 1 | 73 | 7 | 6 | pembrolizumab 200 mg q3w | 9 | true | MSS | 2026-03-15T05:35:59.743228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419450 | REC_0011507 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 12.8 | 75 | male | 3 | 18 | 5.3 | 5 | alectinib 600 mg BID | 10.8 | false | MSS | 2026-03-15T05:35:59.743470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203720 | REC_0011508 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 11.6 | 70 | female | 1 | 4 | 4.8 | 5 | osimertinib 80 mg daily | 8.8 | false | MSS | 2026-03-15T05:35:59.743703+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368769 | REC_0011509 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 12.4 | 69 | female | 0 | 13 | 7.3 | 2 | osimertinib 80 mg daily | 20.7 | false | MSI-H | 2026-03-15T05:35:59.743936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298740 | REC_0011510 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 14.4 | 56 | male | 1 | 4 | 6.1 | 6 | entrectinib 600 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:35:59.744206+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688217 | REC_0011511 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 32 | 13.2 | 67 | female | 0 | 6 | 6.5 | 6 | alectinib 600 mg BID | 13.1 | true | MSS | 2026-03-15T05:35:59.744453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172012 | REC_0011512 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 12.1 | 71 | female | 1 | 7 | 2.8 | 2 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:59.744702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_655295 | REC_0011513 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 15.7 | 46 | male | 0 | 13 | 6 | 2 | sotorasib 960 mg daily | 19.1 | false | MSI-H | 2026-03-15T05:35:59.744979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608624 | REC_0011514 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16.2 | 59 | male | 1 | 18 | 5.8 | 4 | sotorasib 960 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:59.745243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_598375 | REC_0011515 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 19 | 8.6 | 77 | female | 2 | 21 | 5.3 | 0 | alectinib 600 mg BID | 47.6 | false | MSS | 2026-03-15T05:35:59.745487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571260 | REC_0011516 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 12.4 | 57 | male | 0 | 17 | 4.9 | 1 | osimertinib 80 mg daily | 14.2 | true | MSS | 2026-03-15T05:35:59.745732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833208 | REC_0011517 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 17.5 | 63 | male | 1 | 8 | 3.8 | 6 | sotorasib 960 mg daily | 8.4 | true | MSI-H | 2026-03-15T05:35:59.745975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974633 | REC_0011518 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.8 | 72 | male | 1 | 16 | 5.8 | 1 | sotorasib 960 mg daily | 25.3 | true | MSS | 2026-03-15T05:35:59.746234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206885 | REC_0011519 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 10.3 | 60 | female | 1 | 6 | 4.5 | 9 | entrectinib 600 mg daily | 4.4 | false | MSI-H | 2026-03-15T05:35:59.746602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510078 | REC_0011520 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 14.4 | 76 | female | 2 | 1 | 3.7 | 2 | osimertinib 80 mg daily | 20.6 | true | MSI-H | 2026-03-15T05:35:59.746857+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167443 | REC_0011521 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 21 | 15.5 | 59 | female | 1 | 19 | 4.4 | 1 | entrectinib 600 mg daily | 17.8 | true | MSS | 2026-03-15T05:35:59.747102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233413 | REC_0011522 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 7.5 | 59 | female | 0 | 16 | 5 | 7 | osimertinib 80 mg daily | 5.4 | false | MSS | 2026-03-15T05:35:59.747343+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_891797 | REC_0011523 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.6 | 60 | female | 1 | 10 | 5.9 | 5 | alectinib 600 mg BID | 12.4 | true | MSI-H | 2026-03-15T05:35:59.747583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656657 | REC_0011524 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 17.1 | 74 | female | 2 | 28 | 5.1 | 5 | alectinib 600 mg BID | 11.9 | false | MSS | 2026-03-15T05:35:59.747816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794716 | REC_0011525 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.1 | 70 | female | 1 | 17 | 3.3 | 8 | sotorasib 960 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:59.748057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628456 | REC_0011526 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.9 | 71 | female | 2 | 21 | 4.8 | 8 | alectinib 600 mg BID | 14.7 | false | MSI-H | 2026-03-15T05:35:59.748365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813652 | REC_0011527 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 11.5 | 60 | male | 1 | 15 | 6 | 2 | alectinib 600 mg BID | 26.4 | true | MSI-H | 2026-03-15T05:35:59.748635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986108 | REC_0011528 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 5.6 | 70 | male | 1 | 12 | 5.1 | 5 | pembrolizumab 200 mg q3w | 6.2 | false | MSS | 2026-03-15T05:35:59.748890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933863 | REC_0011529 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 2.5 | 71 | male | 1 | 53 | 4.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 5.2 | false | MSS | 2026-03-15T05:35:59.749133+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916214 | REC_0011530 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 7.7 | 72 | male | 2 | 14 | 3.6 | 5 | entrectinib 600 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:59.749374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988820 | REC_0011531 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7.9 | 50 | female | 0 | 51 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.8 | false | MSS | 2026-03-15T05:35:59.749612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737085 | REC_0011532 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 13.3 | 60 | male | 1 | 13 | 4.2 | 4 | alectinib 600 mg BID | 12.2 | false | MSS | 2026-03-15T05:35:59.749974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973413 | REC_0011533 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.5 | 67 | female | 0 | 16 | 5.2 | 1 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:59.750229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_328255 | REC_0011534 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 8.6 | 72 | female | 3 | 19 | 4.7 | 1 | entrectinib 600 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:59.750465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177430 | REC_0011535 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 35 | 13.1 | 71 | male | 2 | 16 | 6.2 | 1 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:59.750708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579545 | REC_0011536 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 35 | 7.7 | 67 | female | 0 | 5 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.8 | false | MSS | 2026-03-15T05:35:59.750948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954104 | REC_0011537 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 11.2 | 71 | male | 2 | 22 | 2.6 | 2 | sotorasib 960 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:59.751190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768271 | REC_0011538 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 10.2 | 52 | male | 0 | 13 | 5.2 | 1 | entrectinib 600 mg daily | 17.3 | true | MSI-H | 2026-03-15T05:35:59.751428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421050 | REC_0011539 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 16.4 | 65 | male | 0 | 18 | 7.1 | 4 | alectinib 600 mg BID | 13.5 | false | MSI-H | 2026-03-15T05:35:59.751670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800686 | REC_0011540 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 9.3 | 69 | female | 1 | 8 | 4.3 | 1 | osimertinib 80 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:59.751904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952052 | REC_0011541 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 6.7 | 69 | female | 0 | 63 | 7.8 | 6 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:35:59.752227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440605 | REC_0011542 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 8.7 | 68 | female | 0 | 10 | 6.2 | 4 | pembrolizumab 200 mg q3w | 14.1 | true | MSS | 2026-03-15T05:35:59.752519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599448 | REC_0011543 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.9 | 55 | male | 0 | 16 | 4.5 | 7 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:35:59.752791+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982100 | REC_0011544 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 11.3 | 53 | female | 0 | 22 | 5.4 | 5 | osimertinib 80 mg daily | 6.2 | true | MSI-H | 2026-03-15T05:35:59.753028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_264986 | REC_0011545 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 34 | 14.9 | 56 | male | 1 | 14 | 6.1 | 4 | alectinib 600 mg BID | 5.9 | true | MSS | 2026-03-15T05:35:59.753374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_774787 | REC_0011546 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 15.1 | 58 | female | 0 | 8 | 5.9 | 4 | entrectinib 600 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:59.753616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981081 | REC_0011547 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 32 | 16.5 | 56 | female | 1 | 16 | 3.5 | 8 | osimertinib 80 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:35:59.753854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812072 | REC_0011548 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 8.2 | 59 | male | 0 | 13 | 5.6 | 2 | sotorasib 960 mg daily | 20.5 | false | MSS | 2026-03-15T05:35:59.754088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_649538 | REC_0011549 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 5.2 | 65 | male | 0 | 48 | 7.2 | 8 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.754321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407699 | REC_0011550 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 4 | 79 | female | 2 | 43 | 6.1 | 5 | pembrolizumab 200 mg q3w | 12.4 | true | MSS | 2026-03-15T05:35:59.754549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558687 | REC_0011551 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 17.5 | 65 | female | 1 | 17 | 5.8 | 6 | alectinib 600 mg BID | 14.7 | true | MSI-H | 2026-03-15T05:35:59.754785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401352 | REC_0011552 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.4 | 61 | female | 1 | 17 | 6.2 | 5 | alectinib 600 mg BID | 8.9 | true | MSI-H | 2026-03-15T05:35:59.755021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860764 | REC_0011553 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 9 | 70 | female | 1 | 17 | 4 | 1 | osimertinib 80 mg daily | 7.3 | false | MSS | 2026-03-15T05:35:59.755249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545097 | REC_0011554 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.4 | 73 | female | 2 | 25 | 7 | 7 | sotorasib 960 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:59.755480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593645 | REC_0011555 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 14.2 | 74 | female | 1 | 8 | 3.9 | 5 | alectinib 600 mg BID | 7.1 | true | MSI-H | 2026-03-15T05:35:59.755712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467061 | REC_0011556 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 8.1 | 63 | female | 1 | 10 | 6.8 | 6 | pembrolizumab 200 mg q3w | 15.7 | false | MSS | 2026-03-15T05:35:59.755943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272769 | REC_0011557 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 14.2 | 69 | female | 1 | 16 | 4.2 | 2 | sotorasib 960 mg daily | 22.9 | false | MSS | 2026-03-15T05:35:59.756285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446322 | REC_0011558 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 11.1 | 69 | female | 0 | 6 | 3.8 | 2 | alectinib 600 mg BID | 10.4 | false | MSI-H | 2026-03-15T05:35:59.756571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828074 | REC_0011559 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.3 | 56 | female | 0 | 16 | 6 | 6 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:59.756812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831007 | REC_0011560 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 17 | 5.7 | 59 | male | 0 | 7 | 5.2 | 2 | pembrolizumab 200 mg q3w | 23.3 | true | MSS | 2026-03-15T05:35:59.757042+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745367 | REC_0011561 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.8 | 68 | female | 1 | 9 | 4 | 7 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:59.757278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826629 | REC_0011562 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 4.2 | 64 | male | 1 | 21 | 7.7 | 2 | osimertinib 80 mg daily | 34.8 | true | MSS | 2026-03-15T05:35:59.757508+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389217 | REC_0011563 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 10.7 | 73 | female | 0 | 21 | 4.6 | 4 | sotorasib 960 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:35:59.757739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734957 | REC_0011564 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 8.5 | 57 | male | 0 | 12 | 5.6 | 1 | osimertinib 80 mg daily | 22.6 | false | MSS | 2026-03-15T05:35:59.757969+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597831 | REC_0011565 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 13 | 6.5 | 66 | female | 0 | 46 | 5.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.9 | false | MSS | 2026-03-15T05:35:59.758196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302063 | REC_0011566 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.4 | 73 | female | 1 | 18 | 5.6 | 5 | alectinib 600 mg BID | 14.1 | false | MSS | 2026-03-15T05:35:59.758428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_958594 | REC_0011567 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 15.9 | 59 | male | 0 | 17 | 3.9 | 2 | osimertinib 80 mg daily | 8.1 | true | MSI-H | 2026-03-15T05:35:59.758666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127387 | REC_0011568 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 12.9 | 62 | male | 1 | 24 | 6.9 | 4 | entrectinib 600 mg daily | 5 | false | MSS | 2026-03-15T05:35:59.758899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251772 | REC_0011569 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 13 | 78 | female | 1 | 15 | 6.4 | 6 | osimertinib 80 mg daily | 13 | true | MSI-H | 2026-03-15T05:35:59.759130+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741013 | REC_0011570 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 10.8 | 68 | male | 1 | 12 | 8.1 | 6 | osimertinib 80 mg daily | 6.3 | false | MSI-H | 2026-03-15T05:35:59.759364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_549186 | REC_0011571 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.2 | 66 | male | 0 | 42 | 5.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.2 | false | MSS | 2026-03-15T05:35:59.759640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996121 | REC_0011572 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 9.2 | 71 | female | 2 | 7 | 3.4 | 4 | pembrolizumab 200 mg q3w | 17.1 | false | MSS | 2026-03-15T05:35:59.759871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355432 | REC_0011573 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 2.6 | 58 | female | 1 | 59 | 4.2 | 8 | pembrolizumab 200 mg q3w | 8.4 | false | MSS | 2026-03-15T05:35:59.760131+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614785 | REC_0011574 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.8 | 50 | male | 0 | 11 | 4.7 | 7 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:59.760372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878126 | REC_0011575 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 6.3 | 66 | female | 0 | 13 | 6.3 | 6 | alectinib 600 mg BID | 10.4 | false | MSS | 2026-03-15T05:35:59.760607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517271 | REC_0011576 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 14.6 | 66 | female | 1 | 7 | 5.3 | 3 | osimertinib 80 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:59.760844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646004 | REC_0011577 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.7 | 65 | male | 1 | 15 | 3.4 | 7 | sotorasib 960 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:35:59.761079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254391 | REC_0011578 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 14 | 12.2 | 47 | female | 0 | 19 | 5.2 | 1 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:59.761314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962649 | REC_0011579 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 5.9 | 57 | male | 0 | 7 | 4.6 | 2 | pembrolizumab 200 mg q3w | 17 | true | MSS | 2026-03-15T05:35:59.761545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379511 | REC_0011580 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14 | 56 | female | 0 | 20 | 4.9 | 6 | entrectinib 600 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:59.761779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_572383 | REC_0011581 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 16.9 | 63 | female | 1 | 18 | 6.3 | 2 | entrectinib 600 mg daily | 7 | false | MSI-H | 2026-03-15T05:35:59.762016+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680698 | REC_0011582 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 11.3 | 75 | female | 2 | 19 | 6.4 | 1 | osimertinib 80 mg daily | 32.1 | true | MSS | 2026-03-15T05:35:59.762249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584124 | REC_0011583 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 15.2 | 61 | female | 1 | 12 | 5.3 | 8 | alectinib 600 mg BID | 10.9 | false | MSS | 2026-03-15T05:35:59.762485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697395 | REC_0011584 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.9 | 61 | female | 1 | 13 | 6.9 | 6 | osimertinib 80 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:35:59.762779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307587 | REC_0011585 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 12.2 | 70 | male | 2 | 10 | 2.8 | 6 | pembrolizumab 200 mg q3w | 8.6 | true | MSS | 2026-03-15T05:35:59.763022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320256 | REC_0011586 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.5 | 58 | male | 0 | 2 | 6.8 | 6 | osimertinib 80 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:59.763257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518103 | REC_0011587 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 7.2 | 66 | female | 1 | 35 | 5.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.2 | true | MSS | 2026-03-15T05:35:59.763487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306256 | REC_0011588 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 13.6 | 73 | male | 0 | 5 | 6.4 | 0 | entrectinib 600 mg daily | 34.5 | false | MSS | 2026-03-15T05:35:59.763722+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135901 | REC_0011589 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.7 | 61 | female | 0 | 14 | 4.6 | 3 | alectinib 600 mg BID | 9.7 | false | MSI-H | 2026-03-15T05:35:59.763957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797636 | REC_0011590 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.2 | 74 | female | 1 | 11 | 7.9 | 1 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:59.764242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_982975 | REC_0011591 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 15 | 60 | female | 0 | 13 | 6.9 | 1 | entrectinib 600 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:35:59.764502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566890 | REC_0011592 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.8 | 61 | male | 1 | 6 | 3.9 | 9 | sotorasib 960 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:59.764737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193914 | REC_0011593 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 14.6 | 70 | female | 2 | 13 | 3.9 | 1 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:59.764972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853578 | REC_0011594 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 15.3 | 58 | female | 0 | 5 | 2.5 | 4 | entrectinib 600 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:59.765215+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247528 | REC_0011595 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.8 | 74 | female | 0 | 48 | 5.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:59.765447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524986 | REC_0011596 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 8.2 | 53 | female | 0 | 14 | 7 | 6 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:59.765679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265310 | REC_0011597 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 11.4 | 67 | female | 1 | 20 | 5.9 | 1 | alectinib 600 mg BID | 21.3 | true | MSS | 2026-03-15T05:35:59.765973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450438 | REC_0011598 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 8.7 | 55 | female | 1 | 15 | 5.5 | 1 | entrectinib 600 mg daily | 23.6 | true | MSS | 2026-03-15T05:35:59.766211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215714 | REC_0011599 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 7.8 | 59 | male | 0 | 13 | 6.7 | 1 | osimertinib 80 mg daily | 21.4 | false | MSS | 2026-03-15T05:35:59.766445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357608 | REC_0011600 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 12.4 | 70 | female | 1 | 21 | 6.8 | 9 | sotorasib 960 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:59.766677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.